Bottneuro AG
- Bottneuro AG
Lichtstrasse 35
4056 Basel, Switzerland Bottneuro Inc.
2261 Market Street #5107
San Francisco, CA 94114, USBottneuro GmbH
Marie-Curie-Straße 8
79539 Lörrach, Germany
Bottneuro AG, a spin-off of the University of Basel was founded in 2021 in Basel, Switzerland.
Bottneuro develops custom made neurostimulators and electroencephalogram devices for neurological conditions, such as Alzheimer's disease. Currently, there are 150,000 people affected by Alzheimer's disease in Switzerland, 1.5 million in Europe, and 6 million in the US.
Why invest in BottNeuro?
The Miamind Neurostimulator is registered as a custom-made medical device at Swissmedic- and MHRA. With Bottneuro GmbH now registered in Germany through EUDAMED, our innovative solutions are available across the EU. Our proprietary technology enables fully personalized neurostimulation therapies for conditions like Alzheimer’s, depression, and stroke. Utilizing advanced MRI imaging, we can tailor treatments to the individual needs of each patient, a method prescribed and overseen by leading neurologists and psychiatrists.
156,900 people
currently live with dementia in Switzerland.
a new case of dementia
is diagnosed
of those affected
are women
is the estimated total annual cost of
dementia care
of the total costs (6.3 billion CHF) are born by the healthcare system, with the remainder covered by families and caregivers.
Backed by our private and institutional investors, we are advancing brain research to bring a new standard of care.
